For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250926:nRSZ9048Aa&default-theme=true
RNS Number : 9048A Aptamer Group PLC 26 September 2025
26 September 2025
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Investor Event and Presentation
Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic
binders for the life sciences industry, is pleased to announce that the
Company will be presenting at the ShareSoc Growth Company Seminar on
Wednesday, 8 October 2025, at the Leonardo Hotel, Brewery Place, Leeds, LS10
1NE. Event registration opens at 4.30 pm and presentations commence at 5.00
pm.
Dr Arron Tolley, Chief Executive Officer, and Andrew Rapson, Chief Financial
Officer, will deliver a presentation, offering investors the opportunity to
engage directly with the Company and gain valuable insights into its recent
progress.
For further information on the ShareSoc Growth Company Seminar and
registration, please visit the event
website: https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-person-event-leeds/
(https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-person-event-leeds/)
A link to Aptamer's presentation will be made available on the Company website
following the event.
No new material information will be disclosed at this event.
- Ends -
For further information, please contact:
Aptamer Group plc +44 (0) 1904 217 404
Dr Arron Tolley, Chief Executive Officer
SPARK Advisory Partners Limited - Nominated Adviser +44 (0) 20 3368 3550
Andrew Emmott / Jade Bayat
Turner Pope Investments (TPI) Limited - Broker +44 (0) 20 3657 0050
James Pope / Andrew Thacker
Northstar Communications Limited - Investor Relations +44 (0) 113 730 3896
Sarah Hollins
About Aptamer Group
Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group develops
Optimer® binders, advanced molecules that work like antibodies by attaching
to specific targets in the body. These binders are used in medicine,
diagnostic tests, and research tools, offering benefits like high stability,
reliable performance, and lower costs compared to traditional antibodies.
Aptamer operates a fee-for-service business in the US$210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners, aiming
for future licensing revenue.
Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.
To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAPPUUABUPAGQA